Clinical Trial Update: Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases [EARLY_Phase 1]

View source ↗

Summary

A Phase 1 pilot trial evaluating nivolumab plus either ipilimumab or relatlimab for surgically resectable melanoma with brain metastases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Melanoma

Drugs mentioned

• Relatlimab (relatlimab)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Metastatic Melanoma, Metastasis to Brain | EARLY_Phase 1 | Status: COMPLETED